| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
LanZhou Foci Pharmaceutical Co.Ltd (SHE: 002644)
002644 Technical Analysis
5
| As on 1st Aug 2025 002644 STOCK Price closed @ 10.43 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 7.46 & Strong Buy for SHORT-TERM with Stoploss of 7.69 we also expect STOCK to react on Following IMPORTANT LEVELS. |
002644STOCK Price
| Open | 10.15 | Change | Price | % |
| High | 11.11 | 1 Day | -0.15 | -1.42 |
| Low | 9.84 | 1 Week | 1.65 | 18.79 |
| Close | 10.43 | 1 Month | 2.36 | 29.24 |
| Volume | 64222661 | 1 Year | 2.13 | 25.66 |
| 52 Week High 11.76 | 52 Week Low 6.21 | ||||
SHE China Most Active Stocks
| 002131 | 3.90 | 1.83% |
| 002437 | 4.04 | 8.89% |
| 300058 | 7.18 | 3.31% |
| 002570 | 7.81 | 2.09% |
| 000813 | 4.70 | -3.09% |
| 300182 | 6.11 | 6.45% |
| 000725 | 4.03 | -0.25% |
| 000558 | 7.37 | 10.00% |
| 002097 | 14.19 | 7.09% |
| 002370 | 7.40 | 9.96% |
SHE China Top Gainers Stocks
SHE China Top Losers Stocks
| 002644 Daily Charts |
002644 Intraday Charts |
Whats New @ Bazaartrend |
002644 Free Analysis |
|
|
002644 Important Levels Intraday
| RESISTANCE | 12.88 |
| RESISTANCE | 12.09 |
| RESISTANCE | 11.61 |
| RESISTANCE | 11.12 |
| SUPPORT | 9.74 |
| SUPPORT | 9.25 |
| SUPPORT | 8.77 |
| SUPPORT | 7.98 |
002644 Forecast August 2025
| 4th UP Forecast | 16.83 |
| 3rd UP Forecast | 14.78 |
| 2nd UP Forecast | 13.51 |
| 1st UP Forecast | 12.24 |
| 1st DOWN Forecast | 8.62 |
| 2nd DOWN Forecast | 7.35 |
| 3rd DOWN Forecast | 6.08 |
| 4th DOWN Forecast | 4.03 |
002644 Weekly Forecast
| 4th UP Forecast | 13.42 |
| 3rd UP Forecast | 12.46 |
| 2nd UP Forecast | 11.87 |
| 1st UP Forecast | 11.27 |
| 1st DOWN Forecast | 9.59 |
| 2nd DOWN Forecast | 8.99 |
| 3rd DOWN Forecast | 8.40 |
| 4th DOWN Forecast | 7.44 |
002644 Forecast2025
| 4th UP Forecast | 22.01 |
| 3rd UP Forecast | 18.3 |
| 2nd UP Forecast | 16 |
| 1st UP Forecast | 13.71 |
| 1st DOWN Forecast | 7.15 |
| 2nd DOWN Forecast | 4.86 |
| 3rd DOWN Forecast | 2.56 |
| 4th DOWN Forecast | -1.15 |
LanZhou Foci Pharmaceutical Co.Ltd ( SHE China Symbol : 002644 )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
002644 Business Profile
LanZhou Foci Pharmaceutical Co.,Ltd., a pharmaceutical company, manufactures and sells traditional Chinese medicines in China. It provides its products in various dosage forms, including pills, tablets, granules, capsules, concentrated decoctions, mixtures, oral liquids, syrups, and medicinal wines under the Min Shan and Foci brands. The company also engages in researching activities for the development of new herbal drugs. It also exports its products to approximately 27 countries, which include the United States, Canada, Japan, Singapore, Indonesia, Thailand, Malaysia, New Zealand, Australia, Russia, Ukraine, Hong Kong, etc. The company was founded in 1929 and is based in Lanzhou, China. LanZhou Foci Pharmaceutical Co.,Ltd. is a subsidiary of Lanzhou Foci Pharmaceutical Factory. Address: 68 Foci Street, Lanzhou, China
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service